Full Press Release Details
Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
to host conference call and webcast at 4:30 pm ET on that day
Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a
clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's
Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for
its quarter ended September 30, 2024 and to provide a corporate update.
participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter
Conference Call when reaching the operator.
4:30 PM Eastern Time
Dial-in: 1-800-343-4136 Participant Dial-in (international): 1-203-518-9843
live audio webcast of the call can be accessed by clicking here or using this link:
transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 7, 2024 by dialing
1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11157233.
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target
the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative
Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver
of innate immune dysfunction and a mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials
to determine if it can treat patients with Mild Alzheimer's disease. Additional therapeutic indications including treatment-resistant
depression and oncology will be pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune , a therapy
developed to prime a patient's NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment
of a wide variety of hematologic and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in
men with metastatic castrate resistant prostate cancer. To learn more, please visit www.inmunebio.com.
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing
of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these
risks and uncertainties. INB03 , XPro1595, and INKmune are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual
future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the
Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company
to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's
business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports
on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance
that may arise after the date of this release.
Moss, CFO (858) 964-3720
Managing Director - LifeSci Advisors